Insider Transactions in Q1 2022 at Aurinia Pharmaceuticals Inc. (AUPH)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 09
2022
|
R. Hector Mac Kay Dunn |
BUY
Open market or private purchase
|
Direct |
5,000
+31.25%
|
$55,000
$11.0 P/Share
|
|
Mar 04
2022
|
George M Milne Jr Director |
BUY
Open market or private purchase
|
Direct |
5,000
+9.09%
|
$50,000
$10.82 P/Share
|
|
Mar 02
2022
|
Robert Bindert Huizinga EVP of Research |
SELL
Open market or private sale
|
Direct |
4,849
-6.53%
|
$58,188
$12.01 P/Share
|
|
Mar 02
2022
|
Robert Bindert Huizinga EVP of Research |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+10.27%
|
-
|
|
Mar 02
2022
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,846
-5.06%
|
$58,152
$12.01 P/Share
|
|
Mar 02
2022
|
Neil Solomons Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+8.15%
|
-
|
|
Mar 02
2022
|
Stephen P. Robertson EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+42.12%
|
-
|
|
Mar 02
2022
|
Peter Greenleaf Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,068
-21.57%
|
$108,816
$12.01 P/Share
|
|
Mar 02
2022
|
Peter Greenleaf Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,300
+40.24%
|
-
|
|
Mar 02
2022
|
Massimilano Colao Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,205
-19.19%
|
$38,460
$12.01 P/Share
|
|
Mar 02
2022
|
Massimilano Colao Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+33.73%
|
-
|
|
Mar 02
2022
|
Joseph M Miller Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,060
-31.64%
|
$36,720
$12.01 P/Share
|
|
Mar 02
2022
|
Joseph M Miller Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+46.78%
|
-
|
|
Mar 02
2022
|
Matthew Maxwell Donley EVP, Ops & Strategy |
SELL
Open market or private sale
|
Direct |
3,052
-15.83%
|
$36,624
$12.01 P/Share
|
|
Mar 02
2022
|
Matthew Maxwell Donley EVP, Ops & Strategy |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+30.6%
|
-
|
|
Mar 02
2022
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,849
-7.53%
|
$58,188
$12.01 P/Share
|
|
Mar 02
2022
|
Michael Robert Martin Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+11.67%
|
-
|
|
Jan 03
2022
|
Joseph P Hagan Director |
SELL
Open market or private sale
|
Direct |
40,000
-52.92%
|
$880,000
$22.94 P/Share
|
|
Jan 03
2022
|
Joseph P Hagan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+47.9%
|
$200,000
$5.08 P/Share
|